{
    "ticker": "SWTX",
    "name": "SpringWorks Therapeutics, Inc.",
    "description": "SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for patients with rare diseases and cancer. Established in 2017 and based in Stamford, Connecticut, the company is dedicated to addressing significant unmet medical needs through the advancement of novel therapies. SpringWorks specializes in targeted therapies and has a robust pipeline primarily centered around its lead product candidate, nirogacestat, an oral gamma-secretase inhibitor currently being investigated for the treatment of desmoid tumors and other oncology indications. The company's mission revolves around a patient-centric approach, emphasizing collaboration with healthcare professionals and communities to deliver transformative therapies. SpringWorks aims to reduce the burden of disease while enhancing the quality of life for patients through its research and development efforts, leveraging cutting-edge science and a commitment to innovation. By focusing on rare disease and oncology, SpringWorks is poised to make a substantial impact in the biopharmaceutical landscape, driving progress in areas where treatment options are limited.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Stamford, Connecticut, USA",
    "founded": "2017",
    "website": "https://www.springworkstx.com",
    "ceo": "Katie Fitzgerald",
    "social_media": {
        "twitter": "https://twitter.com/SpringWorksTx",
        "linkedin": "https://www.linkedin.com/company/springworks-therapeutics"
    },
    "investor_relations": "https://investors.springworkstx.com",
    "key_executives": [
        {
            "name": "Katie Fitzgerald",
            "position": "CEO"
        },
        {
            "name": "Samantha H. W. G. Chung",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Treatments",
            "products": [
                "Nirogacestat"
            ]
        }
    ],
    "seo": {
        "meta_title": "SpringWorks Therapeutics, Inc. | Innovating Rare Disease and Oncology Treatments",
        "meta_description": "Learn about SpringWorks Therapeutics, Inc., a biopharmaceutical company focused on developing innovative therapies for rare diseases and cancer. Explore our pipeline and commitment to patient care.",
        "keywords": [
            "SpringWorks Therapeutics",
            "Nirogacestat",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Oncology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is SpringWorks Therapeutics known for?",
            "answer": "SpringWorks Therapeutics is known for developing innovative therapies for rare diseases and cancer, particularly its lead product candidate, nirogacestat."
        },
        {
            "question": "Who is the CEO of SpringWorks Therapeutics?",
            "answer": "Katie Fitzgerald is the CEO of SpringWorks Therapeutics, Inc."
        },
        {
            "question": "Where is SpringWorks headquartered?",
            "answer": "SpringWorks is headquartered in Stamford, Connecticut, USA."
        },
        {
            "question": "What is SpringWorks' main product?",
            "answer": "SpringWorks' main product candidate is nirogacestat, which is being developed for the treatment of desmoid tumors and other oncology indications."
        },
        {
            "question": "When was SpringWorks Therapeutics founded?",
            "answer": "SpringWorks Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "MRNA",
        "BMRN",
        "ALNY",
        "CRSP"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "ABBV"
    ]
}